Clinical trial
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
NCT00002662
Study timeline
Study start (unknown)1994-08-01Date precision: month
Registry last updated2013-08-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
docetaxelDRUG · verified · RxNorm: docetaxel
paclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Aventis Pharmaceuticalslead sponsor
Mapped research locations
CharlotteNorth Carolina, United States2BostonMassachusetts, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1San AntonioTexas, United States1ClevelandOhio, United States1BirminghamAlabama, United States1CincinnatiOhio, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00002662 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.